Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ZYUS Life Sciences ( (TSE:ZYUS) ) has shared an update.
ZYUS Life Sciences is finalizing site initiation for its Phase 2A clinical trial, UTOPIA-1, which aims to test the safety and efficacy of Trichomylin softgel capsules for managing cancer-related pain. This trial marks a significant step in providing alternative, evidence-based treatments to conventional pain management therapies like opioids, aligning with the growing recognition of cannabinoids’ potential in oncology.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation is a Canadian-based life sciences company specializing in the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. The company is committed to advancing evidence-based therapies, securing intellectual property protection, and obtaining regulatory approval for non-opioid-based pharmaceutical solutions.
Average Trading Volume: 16,928
Technical Sentiment Signal: Sell
Current Market Cap: C$35.28M
For a thorough assessment of ZYUS stock, go to TipRanks’ Stock Analysis page.